Drug Trial News

RSS

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of new clinical data with the Company's targeted anticancer compound, IMGN901.

11 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.

11 Dec 2012

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced new data from its ongoing Phase 1, open-label, dose-escalation trial of IPI-145, the company's potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with advanced hematologic malignancies.

11 Dec 2012

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

New positive Phase II results from an interim analysis of the randomised Phase I/II study involving the company's investigational haematology/oncology compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy were presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, USA.

10 Dec 2012

Results from eribulin and capecitabine phase III comparison trial on metastatic breast cancer

Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival.

10 Dec 2012

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

Active Biotech and Ipsen today announced that the Phase III clinical trial for tasquinimod, a novel compound for the treatment of prostate cancer, is successfully enrolled with over 1,200 randomized patients as planned in the clinical protocol.

10 Dec 2012

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.

10 Dec 2012

Ibrutinib may effectively combat chronic lymphocytic leukemia

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

10 Dec 2012

Mesupron could extend progression-free survival for metastatic breast cancer patients

Previous research has shown that a family of genes, proteins and enzymes called the uPA system (for urokinase plasminogen activator) plays an active role in different facets of cancer's biology, including tumor cell invasion, the spread of metastases, and the growth of a primary tumor. Mesupron- is a new small molecule inhibitor, taken as a pill, that inhibits the uPA system.

10 Dec 2012

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Sanofi announced today new Phase II data showing that treatment with a novel, investigational, selective JAK2 inhibitor (SAR302503) reduced spleen size and improved constitutional symptoms in patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), a hematologic malignancy with unmet medical needs.

10 Dec 2012

Iroko’s submicron indomethacin Phase 3 study on post-surgical acute pain meets primary endpoint

Iroko Pharmaceuticals, LLC today announced that the Phase 3 study evaluating the company's investigational, lower dose submicron indomethacin in post-surgical acute pain met its primary endpoint of demonstrating significant pain relief compared with placebo.

10 Dec 2012

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Celldex Therapeutics, Inc. today announced final results from the Company's randomized Phase 2b EMERGE study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer.

9 Dec 2012

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

Results from the first large, global Phase III study of Halaven (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer were presented today during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.

7 Dec 2012

Novel antidepressant targets brain receptors responsible for learning and memory

A first-of-its-kind antidepressant drug discovered by a Northwestern University professor and now tested on adults who have failed other antidepressant therapies has been shown to alleviate symptoms within hours, have good safety and produce positive effects that last for about seven days from a single dose.

7 Dec 2012

FDA designates two of Cubist’s Phase 3 antibiotic candidates

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated two of the company's Phase 3 antibiotic candidates, CXA-201 (ceftolozane/tazobactam) and CB-315, as Qualified Infectious Disease Products (QIDP).

6 Dec 2012

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13.

6 Dec 2012

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

6 Dec 2012

Scancell announces preliminary results from Part 1 of ImmunoBody vaccine Phase 1/2 MM trial

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, is pleased to announce preliminary results from Part 1 of the Phase 1/2 clinical trial of its DNA ImmunoBody vaccine in patients with Stage III/IV malignant melanoma.

6 Dec 2012

Fexinidazole enters Phase II/III clinical study to treat sleeping sickness

A new oral-only treatment for sleeping sickness has entered Phase II/III clinical study in patients with late-stage sleeping sickness in the Democratic Republic of the Congo (DRC) and soon in Central African Republic (CAR).

6 Dec 2012

Drug Trial News

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

Results from eribulin and capecitabine phase III comparison trial on metastatic breast cancer

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Ibrutinib may effectively combat chronic lymphocytic leukemia

Mesupron could extend progression-free survival for metastatic breast cancer patients

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Iroko’s submicron indomethacin Phase 3 study on post-surgical acute pain meets primary endpoint

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

Novel antidepressant targets brain receptors responsible for learning and memory

FDA designates two of Cubist’s Phase 3 antibiotic candidates

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Scancell announces preliminary results from Part 1 of ImmunoBody vaccine Phase 1/2 MM trial

Fexinidazole enters Phase II/III clinical study to treat sleeping sickness

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News